Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
Subscribe To Our Newsletter & Stay Updated
